Latanoprost - paediatric investigation plan

Latanoprost

Key facts

• Invented name:
  Xalatan
• Active Substance:
  Latanoprost
• Therapeutic area:
  Ophthalmology
• Decision number:
  P/220/2009
• PIP number:
  Latanoprost
• Pharmaceutical form(s):
  Eye drops, solution
• Condition(s) / indication(s):
  Treatment of glaucoma
• Route(s) of administration:
  Ocular use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  03/11/2009
• Compliance procedure number:
  EMEA-C-000011-PIP01-07-M03
• Compliance opinion date:
  19/03/2010
• Compliance outcome:
  Positive

Decision

P/220/2009: European Medicines Agency decision of 3 November 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for latanoprost (Xalatan and associated names) (EMEA-000011-PIP01-07-M03) i...

AdoptedReference Number: EMEA/688850/2009